News

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound a revolutionary, noninvasive therapeutic technology.

Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation and will leverage the Foundation’s established brand, infrastructure, and human and financial resources.

Core activities of IFUS will include:

  • Education of clinicians, allied healthcare providers, and the public around the use of focused ultrasound across indications
  • Meetings and workshops
  • Patient support and advocacy (public policy, regulatory, and reimbursement)
  • Coding, billing, and insurance
  • Clinical guidelines, best practices, and standards of care
  • Training, credentialing, and certification
  • Society and industry partnerships
  • Public relations and communications

“Focused ultrasound has reached a tipping point in clinical adoption, and its role as a game-changing element in the therapeutic armamentarium is now being recognized,” said Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation. “IFUS will help bring this technology into mainstream medicine worldwide by formalizing the clinical, educational, and organizational framework needed for widespread adoption.”

Focused ultrasound is a noninvasive technology that uses high-frequency sound waves, guided by real-time imaging, to treat tissue deep in the body without incisions or radiation. It can exert its effect through multiple mechanisms of action, including destroying tissue, delivering drugs more safely and effectively, and enhancing cancer immunotherapy.

The technology has emerged as one of the most significant medical advances of the 21st century, with more than 1 million patients treated, over 180 indications in various stages of development, and 35 regulatory authorizations worldwide, including 12 by the US Food and Drug Administration. Focused ultrasound is now on a trajectory to treat more than 1 million patients per year.

Nir Lipsman, MD, PhD, neurosurgeon at Sunnybrook Health Sciences Centre and chair of the Division of Neurosurgery at the University of Toronto, will serve as inaugural IFUS board chair.

“As the use of focused ultrasound accelerates globally, IFUS will serve as its clinical home, advancing clinical applications, supporting implementation, and increasing awareness,” said Lipsman. “By connecting physicians across disciplines and regions, the organization will help define the standards, evidence base, and systems needed to make focused ultrasound more accessible to patients worldwide.”

The IFUS founding board members include leading clinicians and researchers representing a wide range of geographies and specialties:

  • Jin Woo Chang, MD, PhD
    Korea University Anam Hospital
  • Sébastien Crouzet, MD, PhD
    Hospices Civils de Lyon & Université Claude Bernard Lyon 1
  • Wladyslaw Gedroyc, MBBS, MRCP, FRCR
    Imperial College Healthcare NHS Trust
  • Catherine Gilmore-Lawless, MBA
    Former Executive, Elekta and GE Healthcare
  • Pejman Ghanouni, MD, PhD
    Stanford University School of Medicine
  • Kullervo Hynynen, PhD
    Sunnybrook Health Sciences Centre
  • Zhang Lian, MD
    Chongqing Haifu Hospital
  • Nir Lipsman, MD, PhD
    Sunnybrook Health Sciences Centre
  • Suzanne LeBlang, MD
    Focused Ultrasound Foundation
  • Clare M. Tempany, MD
    Harvard Medical School & Brigham and Women’s Hospital
  • Joan Vidal-Jove, MD, PhD
    Comprehensive Tumour Center, Barcelona
  • Zhen Xu, PhD
    University of Michigan

IFUS is focused on clinical activities and will complement organizations such as the International Society for Therapeutic Ultrasound (ISTU), which emphasizes basic research and technology development.

Membership will include clinicians, researchers, and trainees, and all individuals involved in focused ultrasound are encouraged to sign up to connect, exchange ideas, and promote and advance this life-changing technology. Founding membership is offered at no cost for the first year. To learn more, see our frequently asked questions. For additional information, contact Paige Rice, IFUS executive director, at price@fusfoundation.org.

Recent News

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the

07/07/2026

Governor Spanberger Announces Virginia Ranked #1 in Nation for Customized Workforce Training

Governor Abigail Spanberger announced today that Virginia is ranked number one in the United States for customized workforce training in the 22nd annual Business Facilities Rankings Report for the fourth consecutive year. Business Facilities, a leading national publication for economic development professionals, recognized the Virginia Talent Accelerator Program for its success in delivering workforce training